TY - JOUR
T1 - Short-term quality of life after myomectomy for uterine fibroids from the COMPARE-UF Fibroid Registry
AU - Laughlin-Tommaso, Shannon K.
AU - Lu, Di
AU - Thomas, Laine
AU - Diamond, Michael P.
AU - Wallace, Kedra
AU - Wegienka, Ganesa
AU - Vines, Anissa I.
AU - Anchan, Raymond M.
AU - Wang, Tracy
AU - Maxwell, G. Larry
AU - Jacoby, Vanessa
AU - Marsh, Erica E.
AU - Spies, James B.
AU - Nicholson, Wanda K.
AU - Stewart, Elizabeth A.
AU - Myers, Evan R.
N1 - Funding Information:
This project was supported by grant number P50HS023418 from the Agency for Healthcare Research and Quality .
Funding Information:
The following authors report consulting or advisory roles with pharmaceutical companies developing products for the treatment of uterine leiomyomata: S.K.L.T., Allergan; E.E.M., Allergan; E.A.S., AbbVie, Bayer, and Myovent; E.M., AbbVie, Allergan, and Bayer. S.K.L.-T. and M.D. also report institutional grants from Bayer. The other authors report no conflict of interest. None of the authors have any financial relationships directly relevant to the manuscript topic.This project was supported by grant number P50HS023418 from the Agency for Healthcare Research and Quality.
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2020/4
Y1 - 2020/4
N2 - Background: Uterine fibroids may decrease quality of life in a significant proportion of affected women. Myomectomy offers a uterine-sparing treatment option for patients with uterine fibroids that can be performed abdominally, laparoscopically (with or without robotic assistance), and hysteroscopically. Quality of life information using validated measures for different myomectomy routes, especially hysteroscopic myomectomy, is limited. Objective: To compare women's perception of their short-term health-related quality of life measures and reported time to return to usual activities and return to work for different routes of myomectomy. Materials and Methods: Comparing Options for Management: Patient-centered Results for Uterine Fibroids (COMPARE-UF) is a prospective nationwide fibroid registry that enrolled premenopausal women seeking treatment for uterine fibroids at 8 clinical sites. For this analysis, we included women undergoing hysteroscopic, abdominal, or laparoscopic myomectomy who completed the postprocedure questionnaire scheduled between 6 and 12 weeks after surgery. Health-related quality of life outcomes, such as pain, anxiety, and return to usual activitie, were assessed for each route. The hysteroscopic myomectomy group had large differences in demographics, fibroid number, and uterine size compared to the other groups; thus, a direct comparison of quality of life measures was performed only for abdominal and laparoscopic approaches after propensity weighting. Propensity weighting was done using 24 variables that included demographics, quality of life baseline measures, and fibroid and uterine measurements. Results: A total of 1206 women from 8 COMPARE-UF sites underwent myomectomy (338 hysteroscopic, 519 laparoscopic, and 349 abdominal). All women had substantial improvement in short-term health-related quality of life and symptom severity scores, which was not different among groups. Average symptom severity scores decreased about 30 points in each group. Return to usual activities averaged 0 days (interquartile range, 0–14 days) for hysteroscopic myomectomy, 21 days (interquartile range, 14–28 days) for laparoscopic myomectomy, and 28 days (interquartile range, 14–35 days) for abdominal myomectomy. After propensity adjustment, quality of life outcomes in the laparoscopic and abdominal myomectomy groups were similar except for more anxiety in the laparoscopic myomectomy group and slightly more pain in the abdominal myomectomy group. After propensity weighting, return to usual activities favored laparoscopic compared to abdominal procedures; median time was the same at 21 days, but the highest quartile of women in the abdominal group needed an additional week of recovery (interquartile range,14.0–28.0 for laparoscopic versus 14.0–35.0 for abdominal, P <.01). Time to return to work was also longer in the abdominal arm (median, 22 days; interquartile range, 14–40 days, versus median, 42; interquartile range, 27–56). Conclusion: Women who underwent myomectomy had substantial improvement in health-related quality of life, regardless of route of myomectomy. After propensity weighting, abdominal myomectomy was associated with a nearly 2-week longer time to return to work than laparoscopic myomectomy.
AB - Background: Uterine fibroids may decrease quality of life in a significant proportion of affected women. Myomectomy offers a uterine-sparing treatment option for patients with uterine fibroids that can be performed abdominally, laparoscopically (with or without robotic assistance), and hysteroscopically. Quality of life information using validated measures for different myomectomy routes, especially hysteroscopic myomectomy, is limited. Objective: To compare women's perception of their short-term health-related quality of life measures and reported time to return to usual activities and return to work for different routes of myomectomy. Materials and Methods: Comparing Options for Management: Patient-centered Results for Uterine Fibroids (COMPARE-UF) is a prospective nationwide fibroid registry that enrolled premenopausal women seeking treatment for uterine fibroids at 8 clinical sites. For this analysis, we included women undergoing hysteroscopic, abdominal, or laparoscopic myomectomy who completed the postprocedure questionnaire scheduled between 6 and 12 weeks after surgery. Health-related quality of life outcomes, such as pain, anxiety, and return to usual activitie, were assessed for each route. The hysteroscopic myomectomy group had large differences in demographics, fibroid number, and uterine size compared to the other groups; thus, a direct comparison of quality of life measures was performed only for abdominal and laparoscopic approaches after propensity weighting. Propensity weighting was done using 24 variables that included demographics, quality of life baseline measures, and fibroid and uterine measurements. Results: A total of 1206 women from 8 COMPARE-UF sites underwent myomectomy (338 hysteroscopic, 519 laparoscopic, and 349 abdominal). All women had substantial improvement in short-term health-related quality of life and symptom severity scores, which was not different among groups. Average symptom severity scores decreased about 30 points in each group. Return to usual activities averaged 0 days (interquartile range, 0–14 days) for hysteroscopic myomectomy, 21 days (interquartile range, 14–28 days) for laparoscopic myomectomy, and 28 days (interquartile range, 14–35 days) for abdominal myomectomy. After propensity adjustment, quality of life outcomes in the laparoscopic and abdominal myomectomy groups were similar except for more anxiety in the laparoscopic myomectomy group and slightly more pain in the abdominal myomectomy group. After propensity weighting, return to usual activities favored laparoscopic compared to abdominal procedures; median time was the same at 21 days, but the highest quartile of women in the abdominal group needed an additional week of recovery (interquartile range,14.0–28.0 for laparoscopic versus 14.0–35.0 for abdominal, P <.01). Time to return to work was also longer in the abdominal arm (median, 22 days; interquartile range, 14–40 days, versus median, 42; interquartile range, 27–56). Conclusion: Women who underwent myomectomy had substantial improvement in health-related quality of life, regardless of route of myomectomy. After propensity weighting, abdominal myomectomy was associated with a nearly 2-week longer time to return to work than laparoscopic myomectomy.
KW - fibroids
KW - hysteroscopy
KW - laparoscopy myomectomy
KW - quality of life
UR - http://www.scopus.com/inward/record.url?scp=85082873341&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082873341&partnerID=8YFLogxK
U2 - 10.1016/j.ajog.2019.09.052
DO - 10.1016/j.ajog.2019.09.052
M3 - Article
C2 - 31678093
AN - SCOPUS:85082873341
SN - 0002-9378
VL - 222
SP - 345.e1-345.e22
JO - American journal of obstetrics and gynecology
JF - American journal of obstetrics and gynecology
IS - 4
ER -